Provided by Tiger Fintech (Singapore) Pte. Ltd.

Everus Construction Group, Inc.

65.16
+1.111.73%
Post-market: 65.160.00000.00%16:20 EDT
Volume:155.08K
Turnover:10.10M
Market Cap:3.32B
PE:21.88
High:66.00
Open:64.33
Low:64.00
Close:64.05
Loading ...

Everus Construction Group, Inc. (ECG) Receives a Rating Update from a Top Analyst

TIPRANKS
·
12 Feb

Everus Construction Group, Inc. (ECG) Gets a Buy from Oppenheimer

TIPRANKS
·
12 Feb

BRIEF-Everus Construction Group Posts Q4 Revenues Of $759.7 Million

Reuters
·
12 Feb

Everus Construction Q4 Earnings Fall, Revenue Rises

MT Newswires Live
·
12 Feb

Everus Construction Group Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
12 Feb

Everus Construction Group Q4 2024 GAAP EPS $0.67 Misses $0.71 Estimate, Sales $759.64M Beat $674.94M Estimate

Benzinga
·
12 Feb

Everus Construction Group Inc - Q4 Diluted EPS of 67 Cents

THOMSON REUTERS
·
12 Feb

Press Release: Everus Reports Strong Fourth Quarter and Full Year 2024 Results, Initiates Guidance for 2025

Dow Jones
·
12 Feb

Everus Construction Group Inc expected to post earnings of 69 cents a share - Earnings Preview

Reuters
·
08 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Feb

Press Release: Everus Construction Group to Hold Fourth Quarter and Full-Year 2024 Results Webcast Feb. 12

Dow Jones
·
30 Jan

HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software

Business Wire
·
29 Jan

Data-Center-Engineering Firms Caught in DeepSeek Selloff

Dow Jones
·
28 Jan

Everus Construction Group, Inc. (ECG) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
27 Jan

Garmin Expands ECG App Availability to Australia, EU

MT Newswires Live
·
16 Jan

Middle Coast Investing Sold its Stake in MDU Resources (MDU)

Insider Monkey
·
09 Jan

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

GlobeNewswire
·
09 Jan

Everus Construction Group Is Maintained at Outperform by Oppenheimer

Dow Jones
·
07 Jan

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy

GlobeNewswire
·
06 Jan